TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05655091
Drug: FLU or CZO as continuous infusion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion FLU or CZO coupled with real-time TDM and subsequent dose adjustment. A loading dose will be administered prior to the first continuous infusion. The loading dose (maximum of 2g as licensed according to the SmPC) and the dose of the continuous infusion will be calculated according to a pharmacokinetic model taking into account patient's characteristics (e.g. age, sex) and the measured drug concentration. The maximum daily dose of FLU and CZO will not exceed 12 grams per day according to the SmPC.
Study: NCT06575751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
Study: NCT06458686
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D is a fat soluble vitamin used for the treatment of many diseases.
Study: NCT06622070
Drug: SPY002-072
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT06333808
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT06333808
Drug: Placebo to match B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT06333808
Drug: Placebo to match BIC/LEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT06105684
Drug: Capecitabine Pill
Normalized name: capecitabine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be given once per day by mouth
Study: NCT06538272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet will be orally administered once daily.
Study: NCT04817241
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05007782
Drug: Denikitug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Intravenously
Study: NCT06541613
Drug: local anesthetic injection (bupivacaine)
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The in-plane technique with a 22G, 80 mm block needle is used to inject 30 ml of 0.25% bupivacaine into the external oblique intercostal plane on both sides.
Study: NCT06511063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo.
Study: NCT06144086
Drug: Foscenvivint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) infusion over 3-4 hours
Study: NCT06197295
Drug: Combination pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5mg and Mirabegron 25mg
Study: NCT05411133
Drug: Cabotamig (ARB202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabotamig (ARB202), Atezolizumab
Study: NCT05780723
Drug: Treatment group: Rectal instillation of QHQYP
Approvals — FDA: no, EMA: no, PMDA: no
Description: QHQYP is decocted in water, with a dose of 100ml each time, and rectal drip before going to bed, once a night, for 8 weeks.
Study: NCT05890001
Drug: BLI5100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take BLI5100 once daily, orally, for up to 29 weeks.
Study: NCT06336798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will take a placebo PO daily
Study: NCT05976828
Drug: IBRX-042
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dose cohort 1: 1e11 virus particles (VP)/dose~* Dose cohort 2: 5e11 VP/dose~* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose
Study: NCT06553027
Drug: CVN424 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 75 mg CVN424 tablet once daily.
Study: NCT06553027
Drug: CVN424 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 150 mg CVN424 tablet once daily.
Study: NCT06553027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo tablet once daily.
Study: NCT06505928
Drug: hepalatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks
Study: NCT05418088
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05168748
Drug: IMJ995 single agent
Normalized name: MISCELLANEOUS AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous administration of IMJ995
Study: NCT05307731
Drug: guideline-based treatment for DM
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: guideline-based treatment for DM
Study: NCT05940883
Drug: Y-2 Sublingual Tablet
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one Y-2 sublingual tablet sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
Study: NCT05940883
Drug: Y-2 Sublingual Tablet
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive two Y-2 sublingual tablets sublingually once daily for Day1 and Day 19 and twice daily for Day 6 to Day 18.
Study: NCT05940883
Drug: Y-2 Sublingual Tablet
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition A, Day 6 with condition B and Day 11 with condition C.
Study: NCT05940883
Drug: Y-2 Sublingual Tablet
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition B, Day 6 with condition C and Day 11 with condition A.
Study: NCT05940883
Drug: Y-2 Sublingual Tablet
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Y-2 sublingual tablet with 3 different conditions once daily for Day1 Day 6 and Day 11. Day 1 with condition C, Day 6 with condition A and Day 11 with condition B.
Study: NCT05940883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, sublingually, single and multiple ascending dosing in group 1 and 2 subjects.
Study: NCT06270030
Drug: Placebo (Vehicle) ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later
Study: NCT05880563
Drug: [18F]-RoSMA-18-d6
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine
Study: NCT05599945
Drug: NNC0581-0001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.
Study: NCT05599945
Drug: Placebo (NNC0581-0001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.
Study: NCT06360796
Drug: [(14)C]ADC189
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject take a single oral dose of about 45 mg (about 100 μCi) \[(14)C\]ADC189 on Day 1 of the study, and be observed by 504 hours.
Study: NCT06217822
Drug: 225Ac-PSMA-Trillium (BAY3563254)
Normalized name: TRILLIUM CHLOROPETALUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous slow injection on Day 1 of a 6 week treatment cycle.
Study: NCT05574166
Drug: SP-8356
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP-8356 demonstrates anti-atherosclerotic and anti-ischaemic activity as a novel CD147 inhibitor.
Study: NCT05574166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for SP-8356 powder
Study: NCT05282277
Drug: Transdermal Estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
Study: NCT05282277
Drug: Matching Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
Study: NCT06387082
Drug: HMPL-506
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.
Study: NCT05394142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator arm with placebo
Study: NCT05394142
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 50 mg/day
Study: NCT05619302
Drug: [68Ga]CBP8 PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous cardiac PET/MRI images will be obtained following injection of \[68Ga\]CBP8
Study: NCT05064202
Drug: Inotropes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone, Dobutamine, Dopamine, Milrinone
Study: NCT05386823
Drug: HF1K16
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF1K16 for Injection doses will be calculated based on subject weight measured at admission, and diluted in sterile saline (0.9% sodium chloride). Doses will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
Study: NCT05386823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be sterile saline (0.9% sodium chloride) which will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
Study: NCT05170009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at baseline, day 4, and day 7.
Study: NCT06001385
Drug: Post-Transplant Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours.~First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.
Study: NCT06001385
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV pre-transplant as part of conditioning regimen
Study: NCT05355402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen-matching placebo will be administered once every 4 weeks by SC injection for up to 49 weeks.
Study: NCT05614089
Drug: NPH or premixed 70/30 (human insulin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: NPH or Premixed 70/30 Formulation: Available as a liquid in a glass vial or glass cartridge (10ml=1000IU).~Route: Bangladesh = syringes or reusable pens; Tanzania = disposable pens~Subcutaneous injection using insulin syringe and needle Amount of each dose: varies depending on baseline basal insulin needs (per usual care or treating clinician) Frequency of dose: once or twice per day (per usual care or treating clinician)~Duration of therapy: 12 months~Participants in both groups will receive the same frequency of blood glucose testing and same intensity of education and counseling (e.g. titration advice according to fasting glucose targets and strategies to avoid hypoglycemia). Participants in both groups will have equal access to test strips (sufficient to test up to 5 times per day during the active titration phase and after 3 times/day).
Study: NCT06255834
Drug: IPG11406
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 0.5 mg, 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 or placebo tablets are orally administered once on Day 1 (Part A) or daily for 10 days from Day 1 to Day 10 (Part B) in a fasted state. Oral doses will be administered with 240 ml of water. Tablets should not be chewed or crushed.~Participants in the FE Cohort will receive a second single dose of IPG11406 following a standardized high fat meal upon ≥4 days washout period after the first dose.~IPG11406 Placebo Placebo tablets: tablets identical to IPG11406 tablets
Study: NCT06375733
Drug: GFH009
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.
Study: NCT06375733
Drug: GFH009
Approvals — FDA: no, EMA: no, PMDA: no
Description: the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.
Study: NCT05285683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral pill
Study: NCT06007638
Drug: LY3876602
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT06007638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT06181760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of matching placebo capsules
Study: NCT04676763
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive normal saline as Negative control
Study: NCT03850964
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical gel capsule without active pharmaceutical ingredient
Study: NCT05138822
Drug: GSK3882347
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3882347 will be administered on each dosing day.
Study: NCT05138822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.
Study: NCT06179069
Drug: ZL-1310
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: ZL-1310
Study: NCT05421598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection solution Subcutaneous injection
Study: NCT05639933
Drug: HT-001 2% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel, 2% active
Study: NCT06197425
Drug: FOLFIRI cures
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging
Study: NCT06197425
Drug: Trifluridine cures
Normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trifluridine tipiracil 35 mg/m2 bid during 5 days/w on week 1 and 2 every 4 weeks, for 6 months or until disease progression on imaging
Study: NCT05513742
Drug: CTX-009
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion administered on day 1 and 15 of every 28-day cycle
Study: NCT05285878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg daily
Study: NCT05048056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1
Study: NCT06269978
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given via IP infusion
Study: NCT04929223
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
Study: NCT04929223
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
Study: NCT05757310
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO and IV
Study: NCT05296356
Drug: OSU6162
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSU6162
Study: NCT05878093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for subcutaneous injection
Study: NCT04830137
Drug: NX-2127
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NX-2127
Study: NCT06144840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06188923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same as active comparator, except placebo dispensed
Study: NCT06520202
Drug: rhPRG4 (450 µg/mL)
Normalized name: urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 drops of rhPRG4 450 µg/mL solution in both eyes
Study: NCT06520202
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile isotonic aqueous solution for ocular administration containing 0.01% polysorbate 20.
Study: NCT05554211
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, control normal saline (NS) irrigation will be administered following gentamicin irrigation. NS irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
Study: NCT05797753
Drug: SAR443820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet by oral administration
Study: NCT05797753
Drug: SAR443820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule by oral administration
Study: NCT05797753
Drug: Erythromycin ethyl succinate
Normalized name: Erythromycin ethyl succinate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet by oral administration
Study: NCT06504862
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin
Study: NCT05135390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times per week
Study: NCT06646627
Drug: B7-H3CART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Levels:~Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3~Arm A IP(± 20%) (flat dose) Dose Level -1: 1 x 107 B7-H3CART Dose Level 1: 5 x 107 B7-H3CART Dose Level 2: 15 x 107 B7-H3CART Dose Level 3: 5 x 108 B7-H3CART~Arm B: IV (± 20%) (weight based) Dose Level -1: 3 x 105 transduced cells/kg Dose Level 1: 1 x 106 transduced cells/kg Dose Level 2: 3 x 106 transduced cells/kg Dose Level 3: 10 x 106 transduced cells/kg
Study: NCT06646445
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (5-fluorouracil/capecitabine ± oxaliplatin 3 months to 6 months) according to the current guidelines, at the investigator's discretion.
Study: NCT06244771
Drug: FMC-376
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT04775706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized, double-blind, placebo-controlled
Study: NCT04948749
Drug: Aggressive medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment).
Study: NCT04948749
Drug: Standard medical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment).
Study: NCT05674552
Drug: Exogenous ketone ester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.
Study: NCT04927299
Drug: Losartan + hydrochlorothiazide in fixed dose
Normalized name: hydrochlorothiazide / losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
Study: NCT06430671
Drug: uncoupled RBCs
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: autologous Red Blood Cells (RBCs)
Study: NCT05616910
Drug: inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNO will be provided by ventilator or nasal cannula for 4 hours each day.
Study: NCT04982237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv infusion
Study: NCT06096116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ
Study: NCT05973864
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m² BID, on days 1-14 of each 21-day cycle; 8 cycles Dose reduction at 825 mg/m² BID during radiotherapy if indicated
Study: NCT05447429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml saline solution will be injected by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
Study: NCT05424276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration gelatin capsule
Study: NCT04495387
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard adjuvat chemotherapy for reast and colo cancer
Study: NCT05388188
Drug: sublingual sufentanil
Normalized name: sufentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dsuvia in patients with SCD VOC as a bridging medication.
Study: NCT06375031
Drug: HR011408 injection; HR011408 injection Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication regimen-A:~HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum
Study: NCT06375031
Drug: NovoRapid®; HR011408 injection Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication regimen-B:~NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum
Study: NCT06375031
Drug: HR011408 injection Placebo; HR011408 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication regimen-C:~HR011408 injection Placebo, ante cibum:~HR011408 injection, post cibum